SLC67A1 and glioma: Our study indicates that aberrant methylation of the SLC22A18 promoter occurred in 15 of the 30 gliomas tested, which correlated with significantly reduced SLC22A18 mRNA and protein expression suggesting that aberrant promoter methylation contributes to decreased SLC22A18 expression in glioma.